These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 17910834

  • 1. [Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative 131-I whole-body scan].
    Cabrera Martín MN, Pasamontes Pingarrón JA, Carreras Delgado JL, Lapeña Gutiérrez L, Delgado Bolton RC, Bittini Copano A, Pérez Castejón MJ, Fernández Pérez C.
    Rev Esp Med Nucl; 2007; 26(5):263-9. PubMed ID: 17910834
    [Abstract] [Full Text] [Related]

  • 2. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E, Aras G, Kucuk NO.
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [Abstract] [Full Text] [Related]

  • 3. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
    Zuijdwijk MD, Vogel WV, Corstens FH, Oyen WJ.
    Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
    [Abstract] [Full Text] [Related]

  • 4. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
    Samanci C, Onal Y, Sager S, Asa S, Ustabasioglu FE, Alis D, Akman C, Sonmezoglu K.
    Curr Med Imaging Rev; 2019 Mar; 15(10):956-964. PubMed ID: 32008523
    [Abstract] [Full Text] [Related]

  • 6. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F, Albano D, Bosio G, Piccardo A, Dib B, Giubbini R.
    Curr Radiopharm; 2016 Mar; 9(3):228-234. PubMed ID: 27210819
    [Abstract] [Full Text] [Related]

  • 7. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL.
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [Abstract] [Full Text] [Related]

  • 8. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K, Pipatrattana R, Tepmongkol S, Sirisalipoch S, Chaiwatanarat T.
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [Abstract] [Full Text] [Related]

  • 9. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S, Aksoy SY, Vatankulu B, Aliyev A, Uslu L, Ozhan M, Sager S, Halac M, Sonmezoglu K.
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A.
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, Chung SK.
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [Abstract] [Full Text] [Related]

  • 12. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
    Ozkan E, Soydal C, Araz M, Aras G, Ibis E.
    Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
    [Abstract] [Full Text] [Related]

  • 13. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
    Ma C, Wang X, Shao M, Zhao L, Jiawei X, Wu Z, Wang H.
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
    [Abstract] [Full Text] [Related]

  • 14. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
    Esteva D, Muros MA, Llamas-Elvira JM, Jiménez Alonso J, Villar JM, López de la Torre M, Muros T.
    Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
    [Abstract] [Full Text] [Related]

  • 15. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM, Cuenca-Cuenca JI, Ruiz-Franco-Baux J, Borrego-Dorado I, Tirado-Hospital JL, Navarro-González E, Vázquez-Albertino R.
    Rev Esp Med Nucl Imagen Mol; 2012 Jul; 31(6):315-21. PubMed ID: 23084014
    [Abstract] [Full Text] [Related]

  • 16. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT.
    Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N.
    Hell J Nucl Med; 2016 Jul; 19(3):208-217. PubMed ID: 27824959
    [Abstract] [Full Text] [Related]

  • 17. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A, Kaznowski J, Wolinski K, Jodlowska E, Michaliszyn P, Kubiak K, Czepczynski R, Ruchala M.
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [Abstract] [Full Text] [Related]

  • 18. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N.
    J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
    [Abstract] [Full Text] [Related]

  • 20. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T, Kowalska A, Lesiak J, Młynarczyk J.
    Nucl Med Rev Cent East Eur; 2014 Feb; 17(2):87-93. PubMed ID: 25088108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.